SOPHiA GENETICS (NASDAQ:SOPH) Reaches New 12-Month High – What’s Next?

SOPHiA GENETICS SA (NASDAQ:SOPH)’s share price reached a new 52-week high during mid-day trading on Monday . The stock traded as high as $6.00 and last traded at $5.9810, with a volume of 195006 shares trading hands. The stock had previously closed at $5.75.

Analysts Set New Price Targets

SOPH has been the topic of several research analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Tuesday, April 21st. BTIG Research reiterated a “buy” rating and set a $8.00 price objective on shares of SOPHiA GENETICS in a report on Monday, June 15th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $7.50.

SOPHiA GENETICS Trading Down 1.2%

The business has a 50-day moving average price of $5.10 and a 200-day moving average price of $4.94. The company has a quick ratio of 1.90, a current ratio of 2.06 and a debt-to-equity ratio of 1.05. The firm has a market capitalization of $478.42 million, a P/E ratio of -10.95 and a beta of 0.98.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). The business had revenue of $21.69 million for the quarter, compared to analyst estimates of $20.40 million. SOPHiA GENETICS had a negative return on equity of 62.74% and a negative net margin of 44.48%.

Insider Buying and Selling at SOPHiA GENETICS

In other SOPHiA GENETICS news, CTO Abhimanyu Verma sold 6,944 shares of the business’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $5.51, for a total value of $38,261.44. Following the transaction, the chief technology officer directly owned 197,456 shares in the company, valued at $1,087,982.56. The trade was a 3.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Philippe Menu sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $5.50, for a total value of $27,500.00. Following the completion of the transaction, the insider directly owned 240,780 shares in the company, valued at $1,324,290. The trade was a 2.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 263,185 shares of company stock valued at $1,341,645. 4.88% of the stock is currently owned by corporate insiders.

Institutional Trading of SOPHiA GENETICS

Hedge funds have recently modified their holdings of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in SOPHiA GENETICS by 246.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock valued at $25,341,000 after buying an additional 5,432,871 shares during the last quarter. Akre Capital Management LLC grew its holdings in shares of SOPHiA GENETICS by 66.2% in the 2nd quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock valued at $11,529,000 after buying an additional 1,481,636 shares during the period. Principal Financial Group Inc. increased its holdings in shares of SOPHiA GENETICS by 0.7% in the first quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock worth $6,976,000 after acquiring an additional 9,800 shares in the last quarter. Archon Capital Management LLC increased its stake in SOPHiA GENETICS by 3.4% during the 4th quarter. Archon Capital Management LLC now owns 441,413 shares of the company’s stock worth $2,061,000 after purchasing an additional 14,342 shares in the last quarter. Finally, Hodges Capital Management Inc. bought a new stake in SOPHiA GENETICS in the 1st quarter valued at $2,157,000. 31.59% of the stock is owned by institutional investors.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.